Grundlæggende statistik
| CIK | 1030206 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vascular Solutions, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| November 17, 2017 |
424B5 Table of Contents CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be Registered Proposed Maximum Offering Price Per Note Proposed Maximum Aggregate Offering Price Amount of Registration Fee 4. |
|
| November 16, 2017 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| November 16, 2017 |
EX-4.2.4 Exhibit 4.2.4 THIRD SUPPLEMENTAL INDENTURE THIRD SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), dated as of October 19, 2017, among NeoTract, Inc. (?NeoTract?), a subsidiary of Teleflex Incorporated, a Delaware corporation (the ?Company?), Teleflex Urology Limited, a subsidiary of the Company (together with NeoTract, the ?Guaranteeing Subsidiaries?), the Company and Wells Fargo B |
|
| November 16, 2017 |
POSASR Table of Contents As filed with the Securities and Exchange Commission on November 16, 2017 Registration No. |
|
| November 16, 2017 |
Computation of ratios of earnings to fixed charges (filed herewith). EX-12.1 Exhibit 12.1 TELEFLEX INCORPORATED COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands, except ratios) Year ended December 31, Nine months ended 2012 2013 2014 2015 2016 October 1, 2017 Earnings: Income (loss) from continuing operations before taxes (165,369 ) 175,730 220,110 244,646 245,725 217,514 Amortization of previously capitalized interest 80 120 161 161 79 59 Capitalize |
|
| November 16, 2017 |
EX-4.2.3 2 d485925dex423.htm EX-4.2.3 Exhibit 4.2.3 SECOND SUPPLEMENTAL INDENTURE SECOND SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of February 28, 2017, among Vascular Solutions, Inc. (the “Guaranteeing Subsidiary”), a subsidiary of Teleflex Incorporated, a Delaware corporation (the “Company”), the Company and Wells Fargo Bank, National Association, as trustee under the Inde |
|
| February 27, 2017 |
Vascular Solutions VASCULAR SOLUTIONS FORM 15-12G 2-27-2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-27605 Vascular Solutions, Inc. (Exact name of registrant as specified in |
|
| February 23, 2017 |
VASC / Vascular Solutions, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.1) Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92231M109 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Re |
|
| February 21, 2017 |
As filed with the Securities and Exchange Commission on February 21, 2017 Registration No. |
|
| February 21, 2017 |
POS AM 1 s001552posam.htm POS AM As filed with the Securities and Exchange Commission on February 21, 2017 Registration No. 333-213063 Registration No. 333-189167 Registration No. 333-168011 Registration No. 333-144688 Registration No. 333-127034 Registration No. 333-114231 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATI |
|
| February 21, 2017 |
POS AM 1 s001552posam.htm POS AM As filed with the Securities and Exchange Commission on February 21, 2017 Registration No. 333-213063 Registration No. 333-189167 Registration No. 333-168011 Registration No. 333-144688 Registration No. 333-127034 Registration No. 333-114231 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATI |
|
| February 21, 2017 |
As filed with the Securities and Exchange Commission on February 21, 2017 Registration No. |
|
| February 21, 2017 |
As filed with the Securities and Exchange Commission on February 21, 2017 Registration No. |
|
| February 21, 2017 |
S-8 POS 1 s001552s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on February 21, 2017 Registration No. 333-54164 Registration No. 333-145719 Registration No. 333-166272 Registration No. 333-191012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-54164 POST-EFFECTIVE AMENDMENT NO. |
|
| February 21, 2017 |
As filed with the Securities and Exchange Commission on February 21, 2017 Registration No. |
|
| February 21, 2017 |
As filed with the Securities and Exchange Commission on February 21, 2017 Registration No. |
|
| February 21, 2017 |
As filed with the Securities and Exchange Commission on February 21, 2017 Registration No. |
|
| February 21, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 16, 2017 (date of earliest event reported) Vascular Solutions, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of |
|
| February 21, 2017 |
As filed with the Securities and Exchange Commission on February 21, 2017 Registration No. |
|
| February 16, 2017 |
VASCULAR SOLUTIONS SHAREHOLDERS APPROVE ACQUISITION BY TELEFLEX Exhibit 99.1 NEWS RELEASE For Immediate Release: Thursday, February 16, 2017 Contact: Vascular Solutions, Inc. Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS SHAREHOLDERS APPROVE ACQUISITION BY TELEFLEX MINNEAPOLIS, Minnesota - Vascular Solutions, Inc. (Nasdaq: VASC) announced that at the Special Meeting of Shareholders held earlier today, Vascular Solutions shareholders vote |
|
| February 16, 2017 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 16, 2017 (date of earliest event reported) Vascular Solutions, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of |
|
| February 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92231M109 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 27, 2017 (date of earliest event reported) Vascular Solutions, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| January 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 27, 2017 (date of earliest event reported) Vascular Solutions, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| January 31, 2017 |
VASC / Vascular Solutions, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92231M109 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and |
|
| January 18, 2017 |
DEFM14A 1 s001489x2defm14a.htm DEFM14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a |
|
| December 22, 2016 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defi |
|
| December 2, 2016 |
8-K 1 form8k.htm VASCULAR SOLUTIONS INC 8-K 12-1-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 1, 2016 (date of earliest event reported) Vascular Solutions, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 |
|
| December 2, 2016 |
VASCULAR SOLUTIONS TO BE ACQUIRED BY TELEFLEX INCORPORATED Exhibit 99.1 NEWS RELEASE For Release: Friday, December 2, 2016, 5:45AM Central Contact: Phil Nalbone, VP Vascular Solutions, Inc. [email protected] (763) 656-4371 VASCULAR SOLUTIONS TO BE ACQUIRED BY TELEFLEX INCORPORATED MINNEAPOLIS, Minnesota ? Vascular Solutions, Inc. (Nasdaq: VASC) today announced that it has entered into a definitive agreement to be acquired by Teleflex Incorporated (NYSE: T |
|
| December 2, 2016 |
EX-2.1 2 ex21.htm EXHIBIT 2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among TELEFLEX INCORPORATED, VIOLET MERGER SUB INC. and VASCULAR SOLUTIONS, INC. dated as of December 1, 2016 TABLE OF CONTENTS Page Article I [Reserved] 2 Article II THE MERGER 2 Section 2.1 The Merger 2 Section 2.2 Closing; Effective Time 2 Section 2.3 Governing Documents; Directors and Officers 3 Sec |
|
| December 2, 2016 |
Amendment to the Bylaws of Vascular Solutions, Inc. (adopted December 1, 2016) Exhibit 3.1 Amendment to the Bylaws of Vascular Solutions, Inc. (adopted December 1, 2016) Pursuant to resolutions unanimously adopted by the board of directors of Vascular Solutions, Inc. on December 1, 2016, the Bylaws of Vascular Solutions, Inc. were amended to include a new Article XII as follows: ARTICLE XII. EXCLUSIVE FORUM Section 12.01. Exclusive Forum. Unless the corporation consents in w |
|
| December 2, 2016 |
Vascular Solutions VASCULAR SOLUTIONS INC DEFA 14A 12-2-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14A-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definit |
|
| December 2, 2016 |
VASCULAR SOLUTIONS TO BE ACQUIRED BY TELEFLEX INCORPORATED Exhibit 99.1 NEWS RELEASE For Release: Friday, December 2, 2016, 5:45AM Central Contact: Phil Nalbone, VP Vascular Solutions, Inc. [email protected] (763) 656-4371 VASCULAR SOLUTIONS TO BE ACQUIRED BY TELEFLEX INCORPORATED MINNEAPOLIS, Minnesota ? Vascular Solutions, Inc. (Nasdaq: VASC) today announced that it has entered into a definitive agreement to be acquired by Teleflex Incorporated (NYSE: T |
|
| December 2, 2016 |
Vascular Solutions VASCULAR SOLUTIONS INC 8-K 12-1-2016 DEFA14A 1 form8k.htm VASCULAR SOLUTIONS INC 8-K 12-1-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 1, 2016 (date of earliest event reported) Vascular Solutions, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-27 |
|
| December 2, 2016 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among TELEFLEX INCORPORATED, VIOLET MERGER SUB INC. and VASCULAR SOLUTIONS, INC. dated as of December 1, 2016 TABLE OF CONTENTS Page Article I [Reserved] 2 Article II THE MERGER 2 Section 2.1 The Merger 2 Section 2.2 Closing; Effective Time 2 Section 2.3 Governing Documents; Directors and Officers 3 Section 2.4 Conversion of Shares; |
|
| December 2, 2016 |
Amendment to the Bylaws of Vascular Solutions, Inc. (adopted December 1, 2016) Exhibit 3.1 Amendment to the Bylaws of Vascular Solutions, Inc. (adopted December 1, 2016) Pursuant to resolutions unanimously adopted by the board of directors of Vascular Solutions, Inc. on December 1, 2016, the Bylaws of Vascular Solutions, Inc. were amended to include a new Article XII as follows: ARTICLE XII. EXCLUSIVE FORUM Section 12.01. Exclusive Forum. Unless the corporation consents in w |
|
| October 24, 2016 |
Vascular Solutions VASCULAR SOLUTIONS, INC 10-Q 9-30-2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULA |
|
| October 24, 2016 |
VASCULAR SOLUTIONS REPORTS THIRD QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Monday, October 24, 2016, 3:05 p.m. Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS THIRD QUARTER RESULTS - Q3 revenue increased 13% to $41.8 million, near the top end of guidance - Q3 GAAP EPS of $0.31, at the top end of guidance - Gu |
|
| October 24, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 24, 2016 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| August 23, 2016 |
CORRESP 1 filename1.htm Vascular Solutions, Inc. 6464 Sycamore Court North Minneapolis, Minnesota 55369 August 23, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Judiciary Plaza 100 F Street N.E. Washington, D.C. 20549 Attn. Ms. Heather Percival Re: Vascular Solutions, Inc. Registration Statement on Form S–3 (File No. 333–213063) Ladies and Gentlemen: Pursuant to |
|
| August 23, 2016 |
CORRESP 1 filename1.htm Vascular Solutions, Inc. 6464 Sycamore Court North Minneapolis, Minnesota 55369 August 23, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Judiciary Plaza 100 F Street N.E. Washington, D.C. 20549 Attn. Ms. Heather Percival Re: Vascular Solutions, Inc. Registration Statement on Form S–3 (File No. 333–213063) Ladies and Gentlemen: Pursuant to |
|
| August 10, 2016 |
Calculation of Ratio of Earnings to Fixed Charges EXHIBIT 12.1 Calculation of Ratio of Earnings to Fixed Charges Year Ended December 31, 2011 2012 2013 2014 2015 (dollars in thousands) Earnings: Income before income taxes $ 15,699 $ 15,892 $ 16,083 $ 19,912 $ 13,641 Add: Fixed charges 445 438 463 337 89 Total earnings $ 16,144 $ 16,330 $ 16,546 $ 20,249 $ 13,730 Fixed Charges: Interest expense $ 13 $ 13 $ 13 $ ? $ ? Estimated interest component o |
|
| August 10, 2016 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Howard Root, James Hennen and Gordon Weber, or any of them (with full power to act alone), as the undersigned?s true and lawful attorneys?in?fact and agents, with full powers of substitution and resubstitution, for the undersigned and in his name, place |
|
| August 10, 2016 |
Vascular Solutions VASCULAR SOLUTIONS S-3 8-10-2016 S-3 1 forms3.htm VASCULAR SOLUTIONS S-3 8-10-2016 As filed with the Securities and Exchange Commission on August 10, 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S–3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Minnesota 41–1859679 (State or other jurisdiction of incorpor |
|
| July 25, 2016 |
Vascular Solutions VASCULAR SOLUTIONS, INC. 10-Q 6-30-2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SOL |
|
| July 25, 2016 |
VASCULAR SOLUTIONS REPORTS SECOND QUARTER RESULTS EXHIBIT 99.1 NEWS RELEASE For Release: Monday, July 25, 2016, 3:05 p.m. Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS SECOND QUARTER RESULTS - Revenue increased 10% to $41.2 million, in the top half of guidance range - Adjusted EPS of $0.33, with corresponding GAAP EPS of |
|
| July 25, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 25, 2016 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inco |
|
| May 27, 2016 |
Exhibit 1.01 Conflict Minerals Report This is the Conflict Minerals Report for Vascular Solutions, Inc. (?Vascular Solutions?, ?we? or ?our?) for the reporting period from January 1, 2015 to December 31, 2015, filed with the United States Securities and Exchange Commission pursuant to Rule 13p-1 under the Securities Exchange Act of 1934. Company Background Vascular Solutions is focused on bringing |
|
| May 27, 2016 |
Vascular Solutions VASCULAR SOLUTIONS, INC. SD 12-31-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 6464 Sycamore Court North Minneapolis, Minnesota 55369 (Address of principal |
|
| May 2, 2016 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 29, 2016 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 25, 2016 |
Vascular Solutions VASCULAR SOLUTIONS, INC 10-Q 3-31-2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SO |
|
| April 25, 2016 |
VASCULAR SOLUTIONS REPORTS FIRST QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Monday, April 25, 2016, 3:05 p.m. Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS FIRST QUARTER RESULTS - Revenue increased 14% to $39.4 million, exceeding the top end of guidance - Adjusted EPS increased 19% to $0.25, exceeding the to |
|
| April 25, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 25, 2016 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| March 28, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8k.htm VASCULAR SOLUTIONS, INC 8-K 3-28-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 28, 2016 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 M |
|
| March 28, 2016 |
EX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”) is entered into on March 28, 2016, by and between Vascular Solutions, Inc. a Minnesota corporation (the “Company”), and Charmaine Sutton (“Consultant”). WHEREAS, Consultant currently serves as the Senior Vice President, Regulatory and Quality Assurance pursuant to that certain Employment |
|
| March 25, 2016 |
Vascular Solutions VASCULAR SOLUTIONS INC. DEF14A 4-29-2016 DEF 14A 1 formdef14a.htm VASCULAR SOLUTIONS INC. DEF14A 4-29-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary |
|
| March 4, 2016 |
8-K 1 form8k.htm VASCULAR SOLUTIONS, INC 8-K 2-29-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 29, 2016 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-2760 |
|
| February 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92231M109 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 10, 2016 |
SC 13G/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92231M109 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 22, 2016 |
VASC / Vascular Solutions, Inc. 10-K - Annual Report - VASCULAR SOLUTIONS, INC. 10-K 12-31-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27605 VASCULAR SOLUTIO |
|
| January 21, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 21, 2016 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| January 21, 2016 |
VASCULAR SOLUTIONS REPORTS FOURTH QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Thursday, January 21, 2016, 3:05pm Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS FOURTH QUARTER RESULTS - Revenue increased 13% to $38.1 million, exceeding the top end of guidance - Adjusted EPS of $0.33, exceeding the top end of gui |
|
| October 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 form10q.htm VASCULAR SOLUTIONS INC 10-Q 9-30-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti |
|
| October 20, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 20, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| October 20, 2015 |
VASCULAR SOLUTIONS REPORTS THIRD QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Tuesday, October 20, 2015, 3:05pm Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS THIRD QUARTER RESULTS - Revenue increased 16% to $37 million, matching the top end of guidance - Adjusted EPS of $0.27 exceeded the top end of guidance; |
|
| July 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 24, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inco |
|
| July 21, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 21, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inco |
|
| July 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SOL |
|
| July 21, 2015 |
VASCULAR SOLUTIONS REPORTS SECOND QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Tuesday, July 21, 2015, 3:05pm Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS SECOND QUARTER RESULTS - Revenue increased 22% to $37.6 million, exceeding the top end of guidance - Adjusted EPS increased 38% to $0.29, exceeding the top |
|
| June 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 3, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of incor |
|
| May 29, 2015 |
Vascular Solutions VASCULAR SOLUTIONS, INC SD 12-31-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 6464 Sycamore Court North Minneapolis, Minnesota 55369 (Address of principal |
|
| May 29, 2015 |
Exhibit 1.01 Conflict Minerals Report This is the Conflict Minerals Report for Vascular Solutions, Inc. (?Vascular Solutions?, ?we? or ?our?) for the reporting period from January 1, 2014 to December 31, 2014, filed with the United States Securities and Exchange Commission pursuant to Rule 13p-1 under the Securities Exchange Act of 1934. Company Background Vascular Solutions is focused on brining |
|
| May 4, 2015 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 1, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of incorp |
|
| April 23, 2015 |
Vascular Solutions VASCULAR SOLUTIONS INC DEFA 14A 4-23-2015 DEFA14A 1 formdefa14a.htm VASCULAR SOLUTIONS INC DEFA 14A 4-23-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant T Filed by a Party other than the Registrant £ Check the appropriate box: £ Prelimina |
|
| April 22, 2015 |
EX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit 10.1 VASCULAR SOLUTIONS, INC. STOCK OPTION AND STOCK AWARD PLAN AS AMENDED APRIL 21, 2015 (SECTION 13 SUBJECT TO SHAREHOLDER APPROVAL AT THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 1, 2015) 1. Purpose of Plan. This Plan shall be known as the “Vascular Solutions, Inc. Stock Option and Stock Award Plan” and is hereinafter referred to as the “Plan”. T |
|
| April 22, 2015 |
EX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit 10.1 VASCULAR SOLUTIONS, INC. STOCK OPTION AND STOCK AWARD PLAN AS AMENDED APRIL 21, 2015 (SECTION 13 SUBJECT TO SHAREHOLDER APPROVAL AT THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 1, 2015) 1. Purpose of Plan. This Plan shall be known as the “Vascular Solutions, Inc. Stock Option and Stock Award Plan” and is hereinafter referred to as the “Plan”. T |
|
| April 22, 2015 |
Vascular Solutions VASCULAR SOLUTIONS INC 8-K 4-21-2015 (STOCK PLAN) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 21, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 22, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 21, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SO |
|
| April 21, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 21, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 21, 2015 |
VASCULAR SOLUTIONS REPORTS FIRST QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Tuesday, April 21, 2015, 3:05pm Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS FIRST QUARTER RESULTS - Revenue increased 16% to $34.6 million, exceeding the top end of guidance - Adjusted EPS, excluding expenses associated with the Sh |
|
| March 27, 2015 |
Vascular Solutions VASCULAR SOLUTIONS, INC DEF 14A 5-1-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (a |
|
| February 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92231M109 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 4, 2015 |
Schedule 13G Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Vascular Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 92231M109 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 3, 2015 |
VASCULAR SOLUTIONS, INC. RESTRICTED STOCK AND CASH ELECTION AWARD Exhibit 10.22 No. R VASCULAR SOLUTIONS, INC. RESTRICTED STOCK AND CASH ELECTION AWARD This RESTRICTED STOCK AND CASH ELECTION AWARD (the “Agreement”) is made this day of , 2015 by and between Vascular Solutions, Inc., a Minnesota corporation (the “Company”) and , an individual resident of (“Participant”). 1. Restricted Stock Award. The Company hereby grants to Participant a restricted stock award |
|
| February 3, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 3, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| February 3, 2015 |
VASCULAR SOLUTIONS REPORTS FOURTH QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Tuesday, February 3, 2015, 3:05 pm Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS FOURTH QUARTER RESULTS - Q4 net revenue increased 15.5% to a record quarterly level of $33.6 million, exceeding the top end of guidance - Q4 GAAP EPS in |
|
| February 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27605 VASCULAR SOLUTIO |
|
| January 28, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 26, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| January 28, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1 to Form 8-K) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 26, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 ( |
|
| January 28, 2015 |
AGREEMENT FOR SALE AND PURCHASE OF PROPERTY [Northgate II, Maple Grove, MN] Exhibit 10.1 AGREEMENT FOR SALE AND PURCHASE OF PROPERTY [Northgate II, Maple Grove, MN] This AGREEMENT FOR SALE AND PURCHASE OF PROPERTY (this “Agreement”) is made and entered into as of January 26, 2015, by and between IRET – LEXCOM, LLC, a North Dakota limited liability company (the “Seller”), and VASCULAR SOLUTIONS, INC., a Minnesota corporation (the “Buyer”). The current notice address of eac |
|
| January 8, 2015 |
VASCULAR SOLUTIONS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2014 REVENUE RESULTS EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 For Release: Thursday, January 8, 2015, 7:00 a.m. Central Time NEWS RELEASE Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2014 REVENUE RESULTS - Fourth quarter revenue of $33.6 million, an increas |
|
| January 8, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 8, 2015 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of in |
|
| November 13, 2014 |
STATEMENT OF VASCULAR SOLUTIONS ON GRAND JURY INDICTMENT Exhibit 99.1 NEWS RELEASE For Immediate Release: Thursday, November 13, 2014 STATEMENT OF VASCULAR SOLUTIONS ON GRAND JURY INDICTMENT MINNEAPOLIS – (November 13, 2014) – In response to an indictment returned today by a federal grand jury in the Western District of Texas, Vascular Solutions, Inc. (Nasdaq: VASC) issued the following statement: “The allegations against us are false and we will contes |
|
| November 13, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 13, 2014 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of |
|
| October 21, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 21, 2014 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| October 21, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULA |
|
| October 21, 2014 |
Exhibit 99.1 NEWS RELEASE For Release: Tuesday, October 21, 2014, 3:05pm Central Time Contact: Vascular Solutions, Inc. Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS THIRD QUARTER RESULTS - Record quarterly revenues increase 14% to $31.9 million, exceeding the top end of guidance - GAAP EPS of $0.15, including the impact of a non-cash deferred tax asset adjustment th |
|
| July 31, 2014 |
VASCULAR SOLUTIONS ANNOUNCES SETTLEMENT OF PATENT LAWSUIT WITH BOSTON SCIENTIFIC Exhibit 99.1 NEWS RELEASE For Release: Wednesday, July 30, 2014, 4:30 pm Central Time Contact: Vascular Solutions, Inc. Howard Root, CEO [email protected] (763) 656-4300 VASCULAR SOLUTIONS ANNOUNCES SETTLEMENT OF PATENT LAWSUIT WITH BOSTON SCIENTIFIC MINNEAPOLIS, Minnesota - Vascular Solutions, Inc. (Nasdaq: VASC) today announced that it has reached a settlement of its patent lawsuit with Boston Scie |
|
| July 31, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 30, 2014 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inco |
|
| July 22, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SOL |
|
| July 22, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 22, 2014 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inco |
|
| July 22, 2014 |
VASCULAR SOLUTIONS REPORTS SECOND QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Tuesday, July 22, 2014, 3:05pm Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS SECOND QUARTER RESULTS - Record quarterly revenues increase 12% to $30.7 million - GAAP earnings per share increase 9% to $0.18 - Raising bottom-end of 2014 |
|
| June 2, 2014 |
Exhibit 1.02 Conflict Minerals Report This is the Conflict Minerals Report for Vascular Solutions, Inc. (“Vascular Solutions” , “we” or “our”) for the reporting period from January 1, 2013 to December 31, 2013, filed with the United States Securities and Exchange Commission pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule 13p-1”). Company Background Vascular Solutions is |
|
| June 2, 2014 |
- VASCULAR SOLUTIONS, INC SD 12-31-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 6464 Sycamore Court North Minneapolis, Minnesota 55369 (Address of principal |
|
| May 1, 2014 |
Submission of Matters to a Vote of Security Holders - VASCULAR SOLUTIONS INC 8-K 4-30-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 30, 2014 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 22, 2014 |
VASCULAR SOLUTIONS REPORTS FIRST QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Tuesday, April 22, 2014, 3:05pm Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS FIRST QUARTER RESULTS - Record revenues increase 15% to $29.9 million, reflecting growth in all three product categories - EPS increases 26% to $0.16, incl |
|
| April 22, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 22, 2014 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 22, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SO |
|
| March 28, 2014 |
- VASCULAR SOLUTIONS, INC DEF 14A 4-30-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant T Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (a |
|
| February 20, 2014 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 18, 2014 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of |
|
| February 20, 2014 |
AGREEMENT FOR SALE AND PURCHASE OF PROPERTY [Northgate I, Maple Grove, MN] EX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit 10.1 AGREEMENT FOR SALE AND PURCHASE OF PROPERTY [Northgate I, Maple Grove, MN] This AGREEMENT FOR SALE AND PURCHASE OF PROPERTY (this “Agreement”) is made and entered into as of February 18, 2014, by and between IRET – PLYMOUTH, LLC, a Minnesota limited liability company (the “Seller”), and VASCULAR SOLUTIONS, INC., a Minnesota corporation (the “Buyer”). T |
|
| February 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92231M109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2014 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Vascular Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 92231M109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 4, 2014 |
VASCULAR SOLUTIONS REPORTS RECORD FOURTH QUARTER RESULTS EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE For Release: Tuesday, February 4, 2014, 3:05 pm Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS RECORD FOURTH QUARTER RESULTS - Q4 revenue increased 15% to a record quarterly level of $29.1 million, exceeding the to |
|
| February 4, 2014 |
VASCULAR SOLUTIONS, INC. EXECUTIVE COMPENSATION RECOUPMENT AGREEMENT EXHIBIT 10.26 VASCULAR SOLUTIONS, INC. EXECUTIVE COMPENSATION RECOUPMENT AGREEMENT This EXECUTIVE COMPENSATION RECOUPMENT AGREEMENT (this “Agreement”) is made this day of , 20 by and between Vascular Solutions, Inc., a Minnesota corporation (the “Company”) and (the “Executive”). WHEREAS, the Board of Directors of the Company (the “Board”) has established the Vascular Solutions, Inc. Executive Comp |
|
| February 4, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8k.htm VASCULAR SOLUTIONS, INC 8-K 2-4-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 4, 2014 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 |
|
| February 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27605 VASCULAR SOLUTIO |
|
| October 22, 2013 |
VASCULAR SOLUTIONS REPORTS THIRD QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Tuesday, October 22, 2013, 3:05 pm Central Time Contact: Vascular Solutions, Inc. James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS THIRD QUARTER RESULTS - Revenue increases 14% to a record quarterly $28 million, exceeding the top end of guidance - Adjusted EPS, excluding the impact |
|
| October 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 form10q.htm VASCULAR SOLUTIONS, INC 10-Q 9-30-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transit |
|
| October 22, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 22, 2013 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| September 11, 2013 |
Vascular Solutions, Inc. 6464 Sycamore Court North Minneapolis, Minnesota 55369 September 11, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Judiciary Plaza 100 F Street N.E. Washington, D.C. 20549 Attn. Mr. Tom Jones Re: Vascular Solutions, Inc. Registration Statement on Form S–3 (File No. 333–189167) Ladies and Gentlemen: Pursuant to Rule 461 of the General Rul |
|
| September 11, 2013 |
CORRESP 1 filename1.htm Vascular Solutions, Inc. 6464 Sycamore Court Minneapolis, Minnesota 55369 September 11, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Judiciary Plaza 100 F Street N.E. Washington, D.C. 20549 Attn. Mr. Tom Jones Re: Vascular Solutions, Inc. Registration Statement on Form S–3 (File No. 333–189167) Ladies and Gentlemen: Pursuant to Rule 461 |
|
| September 10, 2013 |
- VASCULAR SOLUTIONS INC S-3 A NO 2 9-10-2013 Registration No. 333-189167 As filed with the Securities and Exchange Commission on September 10, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S–3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Minnesota 41–1859679 (State or other jurisdiction of incorpor |
|
| September 5, 2013 |
- VASCULAR SOLUTIONS INC S-8 9-5-2013 Registration No. 333- As filed with the Securities and Exchange Commission on September 5, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Minnesota 41-1859679 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 6, 2013 |
- VASCULAR SOLUTIONS, INC S-3 A 8-6-2013 Registration No. 333-189167 As filed with the Securities and Exchange Commission on August 6, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S–3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Minnesota 41–1859679 (State or other jurisdiction of incorporatio |
|
| August 6, 2013 |
August 6, 2013 VIA EDGAR SUBMISSION Daniel Morris Special Counsel Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D. |
|
| July 23, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 23, 2013 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inco |
|
| July 23, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SOL |
|
| July 23, 2013 |
VASCULAR SOLUTIONS REPORTS SECOND QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Tuesday, July 23, 2013, 3:05 pm Central Time Contact: Vascular Solutions, Inc James Hennen, CFO [email protected] (763) 656-4352 Phil Nalbone, VP [email protected] (763) 656-4371 VASCULAR SOLUTIONS REPORTS SECOND QUARTER RESULTS - Revenue increases 11% to a record $27.4 million, with growth in all three of the company’s product categories - EPS increases over |
|
| June 7, 2013 |
Calculation of Ratio of Earnings to Fixed Charges EXHIBIT 12.1 Calculation of Ratio of Earnings to Fixed Charges Year Ended December 31, 2008 2009 2010 2011 2012 (dollars in thousands) Earnings: Income before income taxes $ 3,128 $ 8,166 $ 13,558 $ 15,699 $ 15,892 Add: Fixed charges 314 416 389 445 438 Total earnings $ 3,442 $ 8,582 $ 13,947 $ 16,144 $ 16,330 Fixed Charges: Interest expense $ 62 $ 38 $ 20 $ 13 $ 13 Estimated interest component of |
|
| June 7, 2013 |
EXHIBIT 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Howard Root, James Hennen and Gordon Weber, or any of them (with full power to act alone), as the undersigned’s true and lawful attorneys–in–fact and agents, with full powers of substitution and resubstitution, for the undersigned and in his name, place |
|
| June 7, 2013 |
- VASCULAR SOLUTIONS, INC S-3 6-7-2013 As filed with the Securities and Exchange Commission on June 7, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 7, 2013 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 3, 2013 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of incorp |
|
| April 23, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SO |
|
| April 23, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 23, 2013 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 23, 2013 |
VASCULAR SOLUTIONS REPORTS FIRST QUARTER RESULTS EXHIBIT 99.1 NEWS RELEASE For Release: Tuesday, April 23, 2013, 3:05pm Central Time Contact: James Hennen, CFO Phil Nalbone, VP Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS REPORTS FIRST QUARTER RESULTS - Record revenue increases 10% to $26.1 million, led by strong sales growth in both catheter products and vein products - Adjusted earnings per share, excluding the impact of the prev |
|
| March 29, 2013 |
- VASCULAR SOLUTIONS, INC DEF 14A 5-3-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a |
|
| February 5, 2013 |
REAL ESTATE PURCHASE AND SALE AGREEMENT EXHIBIT 10.41 REAL ESTATE PURCHASE AND SALE AGREEMENT 1. PARTIES The parties to this Real Estate Purchase and Sale Agreement (“Agreement”) dated as of October 22, 2012 (“Effective Date”) are: 1.1. Vascular Solutions, Inc. (“Purchaser”), a Minnesota corporation, whose address is 6464 Sycamore Court, Maple Grove, Minnesota 55369, and 1.2. Dayhu Investments U.S. Corporation, a Nevada corporation, (“S |
|
| February 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27605 VASCULAR SOLUTIO |
|
| February 5, 2013 |
VASCULAR SOLUTIONS, INC. CONDENSED STATEMENTS OF EARNINGS (In thousands, except per share data) EX-99.1 2 ex991.htm EXHIBIT 99.1 EXHIBIT 99.1 NEWS RELEASE For Release: Tuesday, February 5, 2013, 3:05pm Central Time Contact: James Hennen, CFO Phil Nalbone, VP Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS REPORTS RECORD FOURTH QUARTER RESULTS - Q4 net revenue increased 14.5% to $25.3 million - Q4 earnings per share grew 39% to $0.18 - Provides 2013 guidance of $106-$110 million in |
|
| February 5, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8k.htm VASCULAR SOLUTIONS, INC 8-K 2-5-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 5, 2013 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 |
|
| December 31, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 800677106 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| December 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 6, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| December 7, 2012 |
THIRD AMENDMENT TO PROMISSORY NOTE AND CREDIT AGREEMENT EX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit 10.1 THIRD AMENDMENT TO PROMISSORY NOTE AND CREDIT AGREEMENT THIS THIRD AMENDMENT TO PROMISSORY NOTE AND CREDIT AGREEMENT (“Agreement”) is made as of December 6, 2012, by and between VASCULAR SOLUTIONS, INC., a Minnesota corporation (the “Borrower”) and U.S. BANK NATIONAL ASSOCIATION, a national banking association under the laws of the United States of Ame |
|
| December 4, 2012 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 30, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of |
|
| October 29, 2012 |
Entry into a Material Definitive Agreement - VASCULAR SOLUTIONS 8-K 10-24-2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 24, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| October 18, 2012 |
VASCULAR SOLUTIONS, INC. NON-EMPLOYEE DIRECTOR RESTRICTED STOCK AWARD EXHIBIT 10.4 No. R VASCULAR SOLUTIONS, INC. NON-EMPLOYEE DIRECTOR RESTRICTED STOCK AWARD This RESTRICTED STOCK AWARD is made this day of , 20 by and between Vascular Solutions, Inc., a Minnesota corporation (the “Company”) and , an individual resident of (“Director”). 1. Award. The Company hereby grants to Director a restricted stock award of shares (the “Shares”) of Common Stock, par value $.01 p |
|
| October 18, 2012 |
VASCULAR SOLUTIONS, INC. STOCK OPTION AND STOCK AWARD PLAN (Amended and Restated July 27, 2012) EXHIBIT 10.2 VASCULAR SOLUTIONS, INC. STOCK OPTION AND STOCK AWARD PLAN (Amended and Restated July 27, 2012) 1. Purpose of Plan. This Plan shall be known as the “Vascular Solutions, Inc. Stock Option and Stock Award Plan” and is hereinafter referred to as the “Plan”. The Plan shall provide for the issuance of shares of common stock, par value $.01 (the “Common Stock”), of Vascular Solutions, Inc. |
|
| October 18, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 18, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| October 18, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULA |
|
| October 18, 2012 |
Vascular Solutions, Inc. Restricted Share Award Program Non-Employee Directors EXHIBIT 10.3 Vascular Solutions, Inc. Restricted Share Award Program for Non-Employee Directors WHEREAS, the Board of Directors believes that it is in the best interests of the Company and its shareholders to adopt a program providing for an annual award of restricted shares to the Company’s non-employee directors under the Company’s Stock Option and Stock Award Plan (the “Plan”). NOW, THEREFORE, |
|
| October 18, 2012 |
VASCULAR SOLUTIONS REPORTS THIRD QUARTER RESULTS EX-99.1 2 ex991.htm EXHIBIT 99.1 EXHIBIT 99.1 NEWS RELEASE For Release: Thursday, October 18, 2012, 3:05pm Central Time Contact: James Hennen, CFO Phil Nalbone, VP Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS REPORTS THIRD QUARTER RESULTS - Q3 net revenues of $24.6 million - Q3 earnings per share of $0.16 - Provides Q4 revenue guidance of $25.0-$26.0 million and Q4 EPS guidance of $0 |
|
| October 18, 2012 |
EXHIBIT 10.1 ASSET PURCHASE AGREEMENT by and between ST. JUDE MEDICAL, CARDIOLOGY DIVISION, INC., and VASCULAR SOLUTIONS, INC. DATE: AUGUST 16, 2012 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II THE TRANSACTIONS 4 2.1 Purchase and Sale of Assets 4 2.2 Retention of Excluded Liabilities and Excluded Assets 4 2.3 Purchase Price 4 2.4 Closing 4 2.5 Deliveries at the Closing 4 2.6 License G |
|
| August 17, 2012 |
VASCULAR SOLUTIONS ACQUIRES VENTURE® CATHETER FROM ST. JUDE MEDICAL EX-99.1 2 ex991.htm EXHIBIT 99.1 EXHIBIT 99.1 NEWS RELEASE For Release: Friday, August 17, 2012, 8:00am Central Contact: James Hennen, CFO Phil Nalbone, VP Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS ACQUIRES VENTURE® CATHETER FROM ST. JUDE MEDICAL - Clinical niche solution for guidewire directional control in challenging coronary and peripheral interventions, with over seven years |
|
| August 17, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 16, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of in |
|
| August 16, 2012 |
Other Events - VASCULAR SOLUTIONS 8-K 8-14-2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 14, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of in |
|
| August 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 27, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inco |
|
| July 24, 2012 |
VASCULAR SOLUTIONS REPORTS SECOND QUARTER RESULTS EX-99.1 2 ex991.htm EXHIBIT 99.1 EXHIBIT 99.1 NEWS RELEASE For Release: Tuesday, July 24, 2012, 3:05pm Central Time Contact: James Hennen, CFO Phil Nalbone, VP Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS REPORTS SECOND QUARTER RESULTS – Net revenue increased 11% to $24.7 million, exceeding the top end of guidance – EPS increased 17% to $0.15, meeting the top end of guidance – Raisin |
|
| July 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 24, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inco |
|
| July 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SOL |
|
| May 9, 2012 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 4, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of incorp |
|
| April 24, 2012 |
Vascular Solutions, Inc. Incentive Stock Option Agreement EX-10.2 3 ex102.htm EXHIBIT 10.2 EXHIBIT 10.2 Option No. Vascular Solutions, Inc. Incentive Stock Option Agreement This Option Agreement, made January 27, 2012 between Vascular Solutions, Inc., a Minnesota corporation (the "Company") and Howard Root ("Optionee"). The Company has adopted the Vascular Solutions, Inc. Stock Option and Stock Award Plan (the "Plan") which permits issuance of stock opti |
|
| April 24, 2012 |
VASCULAR SOLUTIONS REPORTS FIRST QUARTER RESULTS EX-99.1 2 ex991.htm EXHIBIT 99.1 EXHIBIT 99.1 NEWS RELEASE For Release: Tuesday, April 24, 2012, 3:05 pm Central Time Contact: James Hennen, CFO Phil Nalbone, VP Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS REPORTS FIRST QUARTER RESULTS - Net revenue increases 12% to $23.8 million, exceeding the top end of guidance - EPS increases 20% to $0.12, also exceeding the top end of guidance |
|
| April 24, 2012 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT, made this 27 day of January 2012, is by and between Vascular Solutions, Inc., a Minnesota corporation (the "Company"), and Howard C. Root, a resident of the State of Minnesota (the "Employee"). WHEREAS, Employee and the Company have previously entered into an employment relationship; and WHEREAS, Employee and the Company desire to amend and superce |
|
| April 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SO |
|
| April 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 24, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| March 30, 2012 |
- VASCULAR SOLUTIONS INC DEF 14A 5-4-2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant T Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (a |
|
| February 13, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 800677106 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27605 VASCULAR SOLUTIO |
|
| February 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 1, 2012 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| February 1, 2012 |
VASCULAR SOLUTIONS REPORTS FOURTH QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Wednesday, February 1, 2012, 3:10 pm Central Time Contact: James Hennen, CFO Phil Nalbone, VP Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS REPORTS FOURTH QUARTER RESULTS - Net revenue increases 6% to $22.1 million - EPS increases 8% to $0.13 - Maintaining 2012 guidance for 9% revenue growth and 15% EPS growth, excluding one-time items in 2011 - |
|
| December 22, 2011 |
SECOND AMENDMENT TO PROMISSORY NOTE AND CREDIT AGREEMENT Exhibit 10.1 SECOND AMENDMENT TO PROMISSORY NOTE AND CREDIT AGREEMENT THIS SECOND AMENDMENT TO PROMISSORY NOTE AND CREDIT AGREEMENT (“Agreement”) is made as of December 20, 2011, by and between VASCULAR SOLUTIONS, INC., a Minnesota corporation (the “Borrower”) and U.S. BANK, NATIONAL ASSOCIATION, a national banking association under the laws of the United States of America (the “Lender”). RECITALS |
|
| December 22, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 20, 2011 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of |
|
| October 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 25, 2011 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| October 25, 2011 |
VASCULAR SOLUTIONS REPORTS RECORD THIRD QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Tuesday, October 25, 2011, 3:05 pm Central Time Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS REPORTS RECORD THIRD QUARTER RESULTS - Net revenue increases 22% to record $24.3 million - EPS increases 144% to $0.22 - Revising full-year 2011 guidance to revenues between $90.2-$90.6 million, EPS $0.56-$0.58 |
|
| October 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULA |
|
| August 2, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 2, 2011 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| August 2, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SOL |
|
| August 2, 2011 |
VASCULAR SOLUTIONS REPORTS RECORD SECOND QUARTER RESULTS Exhibit 99.1 NEWS RELEASE For Release: Tuesday, August 2, 2011, 3:05 pm Central Time Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS REPORTS RECORD SECOND QUARTER RESULTS - Net revenue increases 14% to record $22.3 million - EPS increases nearly 45% to $0.13 - $3.7 million in net cash provided by operations - Raising full-year guidance to refl |
|
| April 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 22, 2011 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 28, 2011 |
CHAIRMAN OF THE BOARD AGREEMENT Exhibit 10.1 CHAIRMAN OF THE BOARD AGREEMENT THIS AGREEMENT made as of the 1st day of May 2011, is by and between Vascular Solutions, Inc., a Minnesota corporation (the "Company"), and John Erb, a resident of the State of Minnesota (the "Chairman"). WHEREAS, Chairman and the Company mutually desire to enter into a relationship whereby Chairman will serve as the Chairman of the Board of the Company |
|
| April 28, 2011 |
Vascular Solutions, Inc. Non-Qualified Stock Option Agreement Exhibit 10.3 Option No. V01230 Vascular Solutions, Inc. Non-Qualified Stock Option Agreement This Option Agreement, made April 22, 2011 between Vascular Solutions, Inc., a Minnesota corporation (the "Company") and John Erb ("Optionee"). The Company has adopted the Vascular Solutions, Inc. Stock Option and Stock Award Plan (the "Plan") which permits issuance of stock options for the purchase of sha |
|
| April 28, 2011 |
Exhibit 10.2 AMENDMENT #1 DATED APRIL 22, 2011 TO VASCULAR SOLUTIONS, INC. STOCK OPTION AND STOCK AWARD PLAN AS AMENDED JANUARY 25, 2006 1. The second sentence of Section 19 (a) (i) is amended and restated to read as follows: As used herein, “Outside Director” means a member of the Corporation’s Board of Directors who is not an employee of the Corporation or the Chairman of the Board. All other te |
|
| April 19, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-27605 VASCULAR SO |
|
| April 19, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 19, 2011 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 19, 2011 |
VASCULAR SOLUTIONS, INC. CONDENSED STATEMENTS OF EARNINGS (In thousands, except per share data) Exhibit 99.1 NEWS RELEASE For Release: Tuesday, April 19, 2011, 3:05 pm Central Time Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS ANNOUNCES RECORD FIRST QUARTER RESULTS - Net revenue increases 17% to record $21.3 million - EPS increases 35%, not including litigation gain in first quarter of 2010 - $2.8 million in net cash provided by operat |
|
| March 18, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a |
|
| March 1, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 28, 2011 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of |
|
| February 14, 2011 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 800677106 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 1, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 1, 2011 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| February 1, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27605 VASCULAR SOLUTIO |
|
| February 1, 2011 |
VASCULAR SOLUTIONS, INC. CONDENSED STATEMENTS OF OPERATIONS (In thousands, except per share data) Exhibit 99.1 NEWS RELEASE For Release: Tuesday, February 1, 2011, 3:05 pm Central Time Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS ANNOUNCES RECORD FOURTH QUARTER RESULTS - Net revenue increases 15% to record $20.9 million - Operating income increases 54% to $3.4 million - Earnings per share increases 30%, not including tax benefit - Guida |
|
| February 1, 2011 |
Exhibit 10.28 ZERUSA LIMITED AND VASCULAR SOLUTIONS ZERUSA LIMITED AND VASCULAR SOLUTIONS, INC. AGREEMENT for the sale and purchase of a business together with certain assets relating to Guardian hemostasis valves MASON HAYES+CURRAN Dublin, Ireland www.mhc.ie Contents 1. DEFINITIONS AND INTERPRETATION 3 2. AGREEMENT TO SELL AND PURCHASE 11 3. ASSETS AND LIABILITIES NOT INCLUDED IN THE SALE 12 4. C |
|
| January 28, 2011 |
Exhibit 99.1 NEWS RELEASE For Release: 3:05 CDT, Thursday, January 27, 2011 Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS ACQUIRES ZERUSA LIMITED AND THE GUARDIAN® HEMOSTASIS VALVES Acquisition price of €3.15 million ($4.3 million) paid from existing cash balance Irish manufacturing operations transitioned to Vascular Solutions Acquisition e |
|
| January 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 27, 2011 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| December 28, 2010 |
AGREEMENT TO FILE JOINT SCHEDULE 13D EXHIBIT 1 AGREEMENT TO FILE JOINT SCHEDULE 13D Each of the undersigned, being a record owner or “beneficial owner” of the common stock of Conn’s, Inc. |
|
| December 28, 2010 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per form . |
|
| December 22, 2010 |
FIRST AMENDMENT TO CREDIT AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (“Agreement”) is made as of December 20, 2010, by and between VASCULAR SOLUTIONS, INC., a Minnesota corporation (the “Borrower”) and U.S. BANK, NATIONAL ASSOCIATION, a national banking association under the laws of the United States of America (the “Lender”). RECITALS A. Borrower and Lender entered into that |
|
| December 22, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 20, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of |
|
| November 29, 2010 |
POWER OF ATTORNEY for Executing Forms 3, 4 and 5 and Schedules 13G and 13D Exhibit 1 POWER OF ATTORNEY for Executing Forms 3, 4 and 5 and Schedules 13G and 13D KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints David A. |
|
| November 29, 2010 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Vascular Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 800677106 (CUSIP Number) November 19, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| October 26, 2010 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 23, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| October 26, 2010 |
EX-10.1 2 vasc105360ex10-1.htm SECOND AMENDMENT TO LEASE Exhibit 10.1 SECOND AMENDMENT TO LEASE THIS AMENDMENT (the “Amendment”) is entered into effective as of the 23rd day of October, 2010, between IRET – PLYMOUTH, LLC, a Minnesota limited liability company (“Landlord”), and VASCULAR SOLUTIONS, INC., a Minnesota corporation (“Tenant”). A. Landlord and Tenant are parties to a certain lease agreem |
|
| October 22, 2010 |
EXHIBIT 10.1 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of October 20, 2010, is made and entered into by and among Vascular Solutions, Inc., a Minnesota corporation (“Buyer”), Radius Medical Technologies, Inc., a Delaware corporation (“Radius Technologies”) and Radius Medical, LLC, a Massachusetts limited liability company (“Radius LLC” and, together with R |
|
| October 22, 2010 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 20, 2010 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 20, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| October 20, 2010 |
Exhibit 99.1 NEWS RELEASE For Release: 3:05 CDT, Wednesday, October 20, 2010 Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS ACQUIRES SNARE PRODUCT LINE FROM RADIUS MEDICAL TECHNOLOGIES Acquisition price of $6.5 million paid from existing cash balance Acquisition expected to be accretive in 2011 MINNEAPOLIS, Minnesota — Vascular Solutions, Inc |
|
| October 20, 2010 |
Exhibit 99.1 NEWS RELEASE For Release: Wednesday, October 20, 2010, 3:05 pm Central Time Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS ANNOUNCES RECORD THIRD QUARTER RESULTS; NET REVENUE INCREASES 15% TO $19.9 MILLION MINNEAPOLIS, Minnesota — Vascular Solutions, Inc. (Nasdaq: VASC) today reported financial results for the third quarter ended |
|
| October 20, 2010 |
6464 Sycamore Court Minneapolis, Minnesota 55369 vasc1052428k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 20, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0 |
|
| September 3, 2010 |
EXHIBIT 6 POWER OF ATTORNEY for Executing Forms 3, 4 and 5 and Schedules 13G and 13D KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints David Knight, William B. |
|
| September 3, 2010 |
EX-99.3 4 d75934exv99w3.htm EX-99.3 EXHIBIT 3 POWER OF ATTORNEY for Executing Forms 3, 4 and 5 and Schedules 13G and 13D KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints William B. Keisler and Todd C. Ferguson the undersigned’s true and lawful attorneys-in-fact to: (1) execute, for and on behalf of the undersigned, any one or more Forms 3, 4, and 5 in accordance |
|
| September 3, 2010 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per form . |
|
| September 3, 2010 |
EX-99.2 3 d75934exv99w2.htm EX-99.2 EXHIBIT 2 POWER OF ATTORNEY for Executing Forms 3, 4 and 5 and Schedules 13G and 13D KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints David A. Knight, William B. Keisler and Todd C. Ferguson the undersigned’s true and lawful attorneys-in-fact to: (1) execute, for and on behalf of the undersigned, any one or more Forms 3, 4, an |
|
| September 3, 2010 |
EXHIBIT 4 POWER OF ATTORNEY for Executing Forms 3, 4 and 5 and Schedules 13G and 13D KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints David Knight, William B. |
|
| September 3, 2010 |
AGREEMENT TO FILE JOINT SCHEDULE 13D EX-99.1 2 d75934exv99w1.htm EX-99.1 EXHIBIT 1 AGREEMENT TO FILE JOINT SCHEDULE 13D Each of the undersigned, being a record owner or “beneficial owner” of the common stock of Conn’s, Inc. (“Common Stock”), hereby agrees to jointly file a Schedule 13D with respect to their respective holdings of the Common Stock and to include this agreement as an exhibit to such Schedule 13D. IN WITNESS WHEREOF, ea |
|
| September 3, 2010 |
EX-99.5 6 d75934exv99w5.htm EX-99.5 EXHIBIT 5 POWER OF ATTORNEY for Executing Forms 3, 4 and 5 and Schedules 13G and 13D KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints David Knight, William B. Keisler and Todd C. Ferguson the undersigned’s true and lawful attorneys-in-fact to: (1) execute, for and on behalf of the undersigned, any one or more Forms 3, 4, and 5 |
|
| July 22, 2010 |
VASCULAR SOLUTIONS, INC. MANUFACTURING AND SUPPLY AGREEMENT EXHIBIT 10.3 VASCULAR SOLUTIONS, INC. MANUFACTURING AND SUPPLY AGREEMENT This Manufacturing and Supply Agreement (“Agreement”) is entered into as of April 30, 2010 (the “Effective Date”) by and between Escalon Vascular Access, Inc., a Delaware corporation having its principal place of business at 435 Devon Park Drive, Bldg. 100, Wayne, Pennsylvania 19087 (“Manufacturer”) and Vascular Solutions, In |
|
| July 22, 2010 |
Exhibit 99.1 NEWS RELEASE For Release: Thursday, July 22, 2010, 3:05 pm Central Time Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS ANNOUNCES RECORD SECOND QUARTER RESULTS; NET REVENUE INCREASES 14% TO $19.5 MILLION MINNEAPOLIS, Minnesota - Vascular Solutions, Inc. (Nasdaq: VASC) today reported financial results for the second quarter ended J |
|
| July 22, 2010 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0- |
|
| July 22, 2010 |
EXHIBIT 10.2 ASSET PURCHASE AGREEMENT by and between Vascular Solutions, Inc. and Escalon Vascular IP Holdings, Inc. April 30, 2010 TABLE OF CONTENTS TABLE OF CONTENTS I EXHIBIT LIST III ARTICLE I PURCHASE OF ASSETS; ASSUMPTION OF LIABILITIES 1 1.01 Transfer of Assets 1 1.02 Excluded Assets 3 1.03 Assumption of Liabilities 3 1.04 Excluded Liabilities 3 ARTICLE II PURCHASE PRICE 3 2.01 Amount 3 2.0 |
|
| July 22, 2010 |
EXHIBIT 10.1 ASSET PURCHASE AGREEMENT by and between Vascular Solutions, Inc. and Escalon Vascular Access, Inc. April 30, 2010 TABLE OF CONTENTS TABLE OF CONTENTS I EXHIBIT LIST IV ARTICLE I PURCHASE OF ASSETS; ASSUMPTION OF LIABILITIES 1 1.01 Transfer of Assets 1 1.02 Excluded Assets 3 1.03 Assumption of Liabilities 3 1.04 Excluded Liabilities 4 ARTICLE II PURCHASE PRICE 4 2.01 Amount 4 2.02 Hold |
|
| July 22, 2010 |
EXHIBIT 10.4 GUARANTEE This Guarantee (this “Guarantee”) is delivered by Escalon Medical Corp., a Pennsylvania corporation (“Parent”) for the benefit of Vascular Solutions, Inc., a Minnesota corporation (“Vascular”) and its respective officers, directors, employees, agents and shareholders. WHEREAS, Vascular is entering into that certain Asset Purchase Agreement, dated as of the date hereof, with |
|
| July 22, 2010 |
vascular1035628k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 22, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: |
|
| July 7, 2010 |
Calculation of Ratio of Earnings to Fixed Charges (Dollars in thousands) vasc103341ex12-1.htm - Generated by SEC Publisher for SEC Filing Exhibit 12.1 Calculation of Ratio of Earnings to Fixed Charges (Dollars in thousands) Year Ended December 31, Three Months Ended March 31, 2010 2005 2006 2007 2008 2009 (in thousands) Earnings: Income (loss) before income taxes $ (561 ) $ (1,786 ) $ (4,030 ) $ 3,128 $ 8,166 $ 5,562 Add: Fixed charges 134 366 347 314 416 91 Total earn |
|
| July 7, 2010 |
As filed with the Securities and Exchange Commission on July 7, 2010 Table of Contents As filed with the Securities and Exchange Commission on July 7, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 7, 2010 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Howard Root and James Hennen, or either of them (with full power to act alone), as the undersigned’s true and lawful attorneys–in–fact and agents, with full powers of substitution and resubstitution, for the undersigned and in his name, place and stead, |
|
| June 4, 2010 |
vascular1028138k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 1, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0 |
|
| May 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27 |
|
| May 14, 2010 |
1. Comment: 2. Comment: 3. Comment: 4. Comment: 5. Comment: 6. Comment: May 14, 2010 via edgar submission Jay Mumford Senior Attorney Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D. |
|
| May 14, 2010 |
vascular1024608k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 12, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0 |
|
| May 6, 2010 |
Exhibit 99.1 NEWS RELEASE For Release: 7:00 CDT, Monday, May 3, 2010 Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS ACQUIRES SMARTNEEDLE AND pdACCESS PRODUCTS FROM ESCALON MEDICAL Sales to transition immediately to Vascular Solutions’ direct U.S. sales force Acquisition price of $5.75 million paid from existing cash balance Acquisition expect |
|
| May 6, 2010 |
6464 Sycamore Court Minneapolis, Minnesota 55369 vascular1023358k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 30, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: |
|
| April 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 22, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 23, 2010 |
As filed with the Securities and Exchange Commission on April 23, 2010 Registration No. 333- As filed with the Securities and Exchange Commission on April 23, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Minnesota 41-1859679 (State or other jurisdiction (I.R.S. Employer of incorporation or org |
|
| April 23, 2010 |
VASCULAR SOLUTIONS, INC. EMPLOYEE STOCK PURCHASE PLAN Exhibit 10.1 VASCULAR SOLUTIONS, INC. EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Employee Stock Purchase Plan of Vascular Solutions, Inc. as amended on April 22, 2010. 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company. It is the intention of the Comp |
|
| April 20, 2010 |
Exhibit 99.1 NEWS RELEASE For Release: Tuesday, April 20, 2010, 3:05 pm Central Time Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS ANNOUNCES RECORD FIRST QUARTER RESULTS; NET REVENUE INCREASES 15% TO $18.2 MILLION; NET INCOME INCREASES 270% TO $0.21 PER SHARE MINNEAPOLIS, Minnesota - Vascular Solutions, Inc. (Nasdaq: VASC) today reported fin |
|
| April 20, 2010 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 20, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of inc |
|
| April 20, 2010 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| March 19, 2010 |
SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240. |
|
| February 2, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27605 VASCULAR SOLUTIO |
|
| February 2, 2010 |
CREDIT AGREEMENT THIS CREDIT AGREEMENT, dated as of December 21, 2009, is by and between Vascular Solutions, Inc. |
|
| February 2, 2010 |
SECURITY AGREEMENT This Security Agreement (this “Agreement”) is made as of December 21, 2009, by and between Vascular Solutions, Inc. |
|
| February 2, 2010 |
EX-10.14 4 vascular100390ex10-14.htm PROMISSORY NOTE REVOLVING PROMISSORY NOTE December 21, 2009 $10,000,000 Minneapolis, Minnesota FOR VALUE RECEIVED, VASCULAR SOLUTIONS, INC., a Minnesota corporation (“Borrower”) hereby promises to pay to the order of U.S. BANK NATIONAL ASSOCIATION, a national banking association organized under the laws of the United States, its endorsees, successors and assign |
|
| February 2, 2010 |
EX-99.1 2 vascular100450ex99-1.htm PRESS RELEASE DATED FEBRUARY 2, 2010 Exhibit 99.1 NEWS RELEASE For Release: Tuesday, February 2, 2010, 3:05 pm Central Time Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS ANNOUNCES RECORD FOURTH QUARTER RESULTS; NET REVENUE INCREASES 11% TO RECORD $18.2 MILLION; NET INCOME OF $0.10 PER SHARE MINNEAPOLIS, Min |
|
| February 2, 2010 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 29, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| January 21, 2010 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 21, 2010 (date of earliest event reported) VASCULAR SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 0-27605 Minnesota 41-1859679 (State or other jurisdiction of i |
|
| January 21, 2010 |
Exhibit 99.1 NEWS RELEASE For Immediate Release: Thursday, January 21, 2010 Contact: Howard Root, CEO James Hennen, CFO Vascular Solutions, Inc. (763) 656-4300 VASCULAR SOLUTIONS RECEIVES $3.5 MILLION AS PAYMENT OF MONETARY JUDGMENT IN LITIGATION WITH MARINE POLYMER TECHNOLOGIES MINNEAPOLIS, Minnesota - Vascular Solutions, Inc. (Nasdaq:VASC) announced that it has received $3.5 million from Marine |
|
| January 6, 2010 |
SEPARATION AGREEMENT AND GENERAL RELEASE Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (“Agreement”) is entered into by and between James H. Quackenbush (“Employee”) and Vascular Solutions, Inc. (“Employer”). WHEREAS, Employee’s services for the Employer will terminate on the close of business on February 5, 2010; and WHEREAS, Employee and Employer desire to fully and finally settle a |
|
| January 6, 2010 |
VASCULAR SOLUTIONS FORM 8-K DATED DECEMBER 31, 2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
